Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma
Public ClinicalTrials.gov record NCT01238861. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to evaluate the effect of multiple-dose subcutaneous administrations of MEDI-563 on adults with uncontrolled asthma.
Study identification
- NCT ID
- NCT01238861
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 964 participants
Conditions and interventions
Conditions
Interventions
- Benralizumab 2 mg Biological
- Benralizumab 20 mg Biological
- Benralizumab 100 mg Biological
- Placebo Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2010
- Primary completion
- Feb 28, 2013
- Completion
- Jul 31, 2013
- Last update posted
- Nov 16, 2016
2010 – 2013
United States locations
- U.S. sites
- 27
- U.S. states
- 20
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | — | — |
| Research Site | Los Angeles | California | — | — |
| Research Site | Orange | California | — | — |
| Research Site | San Diego | California | — | — |
| Research Site | Stockton | California | — | — |
| Research Site | Colorado Springs | Colorado | — | — |
| Research Site | Denver | Colorado | — | — |
| Research Site | Waterbury | Connecticut | — | — |
| Research Site | Kissimmee | Florida | — | — |
| Research Site | Tampa | Florida | — | — |
| Research Site | Stockbridge | Georgia | — | — |
| Research Site | Normal | Illinois | — | — |
| Research Site | Baltimore | Maryland | — | — |
| Research Site | Rochester | Minnesota | — | — |
| Research Site | St Louis | Missouri | — | — |
| Research Site | Bellevue | Nebraska | — | — |
| Research Site | Summit | New Jersey | — | — |
| Research Site | Rochester | New York | — | — |
| Research Site | Winston-Salem | North Carolina | — | — |
| Research Site | Cincinnati | Ohio | — | — |
| Research Site | Oklahoma City | Oklahoma | — | — |
| Research Site | Blue Bell | Pennsylvania | — | — |
| Research Site | Pittsburgh | Pennsylvania | — | — |
| Research Site | Warwick | Rhode Island | — | — |
| Research Site | Boerne | Texas | — | — |
| Research Site | San Antonio | Texas | — | — |
| Research Site | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01238861, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 16, 2016 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01238861 live on ClinicalTrials.gov.